Published By : 04 May 2016 | Published By : QYRESEARCH
The global insulin delivery devices market is witnessing a significant rise in its market valuation. The increasing prevalence of diabetes across the world, fueled by the rising base of obese as well as geriatric population, is the key driving force behind this remarkable growth of this market. Insulin pumps, insulin pens, insulin jet injectors, and insulin syringes are the key insulin delivery devices available in the global arena.
Apart from this, the advancement in insulin delivery devices and the growing awareness among people regarding diabetes and its treatments are also aiding the global market for insulin delivery devices considerably. However, the high cost associated with insulin analog and the rising concerns over the risks and complications related to the delivery of insulin is expected to hamper the growth of this market in the nearing future.
Increased Prevalence of Diabetes Drives North America Insulin Delivery Devices Market
North America leads the global market for insulin delivery devices. The soaring prevalence of diabetes is the key factor driving the growth of this market. The rising awareness regarding glucose control and the increasing number of flexible treatment options is boosting the North America insulin delivery devices market significantly.
Insulin pumps is likely to enjoy a significant demand in North America, owing to the shift in the preferences of patients from conventional devices such as syringes and pens. On the other hand, insulin pens are the most demanded insulin delivery devices in Europe and, together with syringes, they also drive the insulin delivery devices market in Asia Pacific.
B. Braun Melsungen AG, Ypsomed Holding AG, Sanofi, Abbott Laboratories, Novo Nordisk A/S, Eli Lilly and Co., Insulet Corp., Roche, Medtronic Inc., Becton Dickinson, and Animas Corp. are the major international producers of insulin delivery devices in the global arena.